24 Oct 2025 | 5 Mins Read
Cipla shares decline following Eli Lilly deal
Flipitmoney
Cipla Ltd shares fell 3% on October 24 after partnering with Eli Lilly to sell Lilly's weight-loss drug, Mounjaro, under the brand name Yurpeak in India. Cipla will market the drug, priced the same as Mounjaro, which saw sales more than double in India within months of its launch. Analysts estimate the Indian GLP-1 market may reach $1 billion in four years, adding 3% to Cipla's domestic revenue.